palbociclib + anastrozole + letrozole + exemestane + hydroxychloroquine

This combination regimen is being investigated by Sun Yat-Sen Memorial Hospital for the treatment of hormone receptor-positive (HR+), HER2-negative advanced breast cancer. It consists of the CDK4/6 inhibitor palbociclib, an aromatase inhibitor (anastrozole, letrozole, or exemestane), and the autophagy inhibitor hydroxychloroquine. The rationale for adding hydroxychloroquine is to inhibit autophagy, a survival mechanism by which cancer cells may develop resistance to CDK4/6 inhibition and endocrine therapy. The regimen is being evaluated in a Phase III trial comparing standard and high-dose palbociclib combinations to standard endocrine therapy plus palbociclib to determine if the addition of an autophagy inhibitor can improve clinical outcomes in patients with advanced disease.

Other names

Hydroxychloroquine and High-Dose Palbociclib in HR+/HER2- Advanced Breast Cancer